Investing.com UK - Financial Markets Worldwide
Get 40% Off
Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now

Moderna Likely To Report Q4 Loss; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Published 22/02/2024, 07:32
© Reuters. Moderna Likely To Report Q4 Loss; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Benzinga - by Avi Kapoor, Benzinga Staff Writer.

Moderna, Inc. (NASDAQ: MRNA) is expected to release earnings results for its fourth quarter, before the opening bell on Feb. 22, 2024.

Analysts expect the Cambridge, Massachusetts-based company to report quarterly earnings at 97 cents per share, versus year-ago earnings of $3.61 per share. Moderna is projected to report quarterly revenue of $2.5 billion, compared to $5.08 billion in the year-earlier quarter, according to data from Benzinga Pro.

Moderna, last month, announced a series of business updates and progress on the company’s pipeline of mRNA medicines at the 42nd annual JPMorgan Healthcare Conference. The company said it came into 2024 with 45 total therapeutic and vaccine programs. Nine of those programs are in late-stage development.

Moderna shares rose 0.7% to close at $87.59 on Wednesday.

Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.

Let’s have a look at how Benzinga’s most-accurate analysts have rated the company in the recent period.

  • Oppenheimer analyst Hartaj Singh upgraded the stock from Perform to Outperform with a price target of $142 on Jan. 2, 2024. This analyst has an accuracy rate of 66%.
  • JP Morgan analyst Jessica Fye maintained a Neutral rating and cut the price target from $93 to $90 on Dec. 1, 2023. This analyst has an accuracy rate of 65%.
  • Canaccord Genuity analyst Bill Maughan initiated coverage on the stock with a Hold rating and a price target of $82 on Nov. 29, 2023. This analyst has an accuracy rate of 76%.
  • Morgan Stanley analyst Matthew Harrison maintained an Equal-Weight rating and slashed the price target from $128 to $123 on Aug. 4, 2023. This analyst has an accuracy rate of 61%.
  • B of A Securities analyst Geoff Meacham maintained a Neutral rating and cut the price target from $175 to $150 on Aug. 4, 2023. This analyst has an accuracy rate of 61%.
3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Read This Next: Top 5 Industrials Stocks That May Collapse This Quarter

Latest Ratings for MRNA

Mar 2022Deutsche BankMaintainsHold
Feb 2022Morgan StanleyMaintainsEqual-Weight
Feb 2022SVB LeerinkMaintainsUnderperform

View the Latest Analyst Ratings

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.